Brief: Cytodyn Reached Its Enrollment Target For Phase 2 COVID-19 Trial For Mild To Moderate Indication
11/06/2020 22:37
June 11 (Reuters) - Cytodyn Inc CYDY.PK :
* CYTODYN REACHED ITS ENROLLMENT TARGET FOR PHASE 2 COVID-19
TRIAL
FOR MILD TO MODERATE INDICATION – PRIMARY END POINT ANNOUNCEMENT
IS NEXT
Source text for Eikon: ID:nGNXJhMK
Further company coverage: CYDY.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cytodyn
See all newsBrief: Cytodyn Appoints Robert E. Hoffman As Chief Executive Officer
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer